News
LPTX
3.170
-3.65%
-0.120
Weekly Report: what happened at LPTX last week (0415-0419)?
Weekly Report · 3d ago
Leap Therapeutics 13G Filing Shows Gilead Sciences, Inc. Reported A 13.9% Stake In The Co As Of April 10, 2024
Benzinga · 6d ago
GILEAD SCIENCES, INC REPORTS 13.9% PASSIVE STAKE IN LEAP THERAPEUTICS AS OF APRIL 10- SEC FILING
Reuters · 6d ago
Weekly Report: what happened at LPTX last week (0408-0412)?
Weekly Report · 04/15 12:08
Top 10 stocks with upwards and downwards daily percentage change - Piper Sandler
Piper Sandler published the top 10 stocks with upwards and downwards daily percentage change as of Thursday. The S&P 500 (SP500) is vulnerable to a possible 5-10% pullback in upcoming weeks or months, analysts say. High-interest rates, inflation, and mediocre breadth are making the market vulnerable to pullback, Piper Sandler says.
Seeking Alpha · 04/12 15:34
Leap Therapeutics Shares Rise 9% After Pricing of Private Placement
Leap Therapeutics shares were up 9% at $3.31 in recent trading. The stock is down about 20% in the past 12 months. The company entered a securities purchase agreement with a group of institutional investors to issue and sell 12.7 million shares in a private placement.
Dow Jones · 04/11 14:29
Leap Therapeutics To Sell $40 Mln Of Shares In Private Placement; Stock Up Over 14%
NASDAQ · 04/11 13:06
LEAP THERAPEUTICS INC: INTENDS TO USE NET PROCEEDS FROM FINANCING TO FUND CONTINUED DEVELOPMENT OF ITS LEAD MONOCLONAL ANTIBODY PROGRAM, DKN-01
Reuters · 04/11 12:30
LEAP THERAPEUTICS ANNOUNCES $40 MILLION PRIVATE PLACEMENT
Reuters · 04/11 12:30
Press Release: Leap Therapeutics Announces $40 Million Private Placement
Leap Therapeutics Announces $40 million Private Placement. Net proceeds are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01 clinical trial and development program. The company intends to use the net proceeds to fund the continued development of its lead monoclonal antibody program.
Dow Jones · 04/11 12:30
Weekly Report: what happened at LPTX last week (0401-0405)?
Weekly Report · 04/08 12:15
Weekly Report: what happened at LPTX last week (0325-0329)?
Weekly Report · 04/01 12:11
Weekly Report: what happened at LPTX last week (0318-0322)?
Weekly Report · 03/25 12:15
12 Health Care Stocks Moving In Wednesday's After-Market Session
XTL Biopharmaceuticals (NASDAQ:XTLB) shares moved upwards by 13.9% to $2.71 during Wednesday's after-market session. The company's Q4 earnings report came out 2 days ago. Jaguar Health and Leap Therapeutics were among the gainers.
Benzinga · 03/20 21:34
Leap Therapeutics Price Target Cut to $9.00/Share From $11.00 by Baird
Dow Jones · 03/19 11:20
Leap Therapeutics Is Maintained at Outperform by Baird
Dow Jones · 03/19 11:20
Baird Maintains Outperform on Leap Therapeutics, Lowers Price Target to $9
Benzinga · 03/19 11:09
Leap Therapeutics Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Dow Jones · 03/19 10:57
HC Wainwright & Co. Reiterates Buy on Leap Therapeutics, Maintains $7 Price Target
Benzinga · 03/19 10:48
Leap Therapeutics: Promising Clinical Outcomes and Upcoming Catalysts Bolster Buy Rating
An analyst from H.C. Wainwright maintained the Buy rating on Leap Therapeutics (LPTX) with a price target of $7.00. The company is developing novel therapies to treat cancer patients. The analyst sees potential for value creation in the near term.
TipRanks · 03/19 10:19
More
Webull provides a variety of real-time LPTX stock news. You can receive the latest news about Leap Therapeutic through multiple platforms. This information may help you make smarter investment decisions.
About LPTX
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. It also has two preclinical antibody programs, FL-302 and FL-501. FL-302 is a Claudin18.2/CD137 (also known as 4-1BB) bispecific antibody that is in preclinical development. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.